Nataliya Kolganova

Dr. Nataliya Kolganova

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2022 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
PFPavel Frolov
Pavel Frolov
MHMoscow Morozov Children’s City Clinical Hospital
Moscow Morozov Children’s City Clinical Hospital
NKNataliya Kolganova
Nataliya Kolganova
DODmitry Ovsyannikov
Dmitry Ovsyannikov
IOIrina Ozerskaia
Irina Ozerskaia
VGV.V. Gorev
V.V. Gorev
Despite the manifestations of primary ciliary dyskinesia (PCD) in the neonatal period or in the first year of life, the diagnosis of this rare disease is usually established at the age of 4–7 years. The aim of the study was to search for reserves for early diagnosis of PCD. Materials and methods of research: 17 patients were observed with PCD, confirmed on the basis of the PICADAR scale, highspeed light video microscopy (all patients) and transmission electron microscopy (in 3 patients) of the mucous biopsy of the respiratory membrane using a genetic study (in one patient). Results: all patients were born full-term; neonatal respiratory distress syndrome (RDS) was observed in 71% of patients; the median duration of mechanical ventilation/oxygen therapy was 14 [7; 21] days; lateralization abnormalities were found in 35% of patients; all patients had persistent nasal congestion and/or rhinorrhea, 94% had chronic or recurrent sinusitis, otitis, recurrent pneumonia, chest x-ray and computed tomography (CT) scans in 71% had atelectasis with constant localization in the middle lobe, 12 of 15 patients, traced in the follow-up, – bronchiectasis (BE), also mainly in the middle lobe (in 9 patients). The average age at diagnosis was 5 [1.75; 7] years, patients with an established diagnosis over the age of 3 years were more often diagnosed with BE. The median of PICADAR scores was 7 [6; 8] points. Conclusions: to establish early diagnosis of PCD, it is important to consider neonatal RDS, lateralization of organs, difficulty in nasal breathing, starting from the first half of life.

30 December 2024 in Polymers
Verified
Journal Article
Open access
PDF file
IZIgor Zlotnikov
Igor Zlotnikov
AEAlexander Ezhov
Alexander Ezhov
NKNataliya Kolganova
Nataliya Kolganova
DODmitry Ovsyannikov
Dmitry Ovsyannikov
NBNatalya Georgievna Belogurova
Natalya Georgievna Belogurova
Elena V. KudryashovaElena V. Kudryashova
Elena V. Kudryashova
Macrophage (Mph) polarization and functional activity play an important role in the development of inflammatory lung conditions. The previously widely used bimodal classification of Mph into M1 and M2 does not adequately reflect the full range of changes in polarization and functional diversity observed in Mph in response to various stimuli and disease states. Here, we have developed a model for the direct assessment of Mph from bronchial alveolar lavage fluid (BALF) functional alterations, in terms of phagocytosis activity, depending on external stimuli, such as exposure to a range of bacteria (E. coli, B. subtilis and L. fermentum). We have employed polymeric mannosylated ligands (the “trapping ligand”) specifically targeting the CD206 receptor to selectively isolate activated Mph from the BALF of patients with pulmonary inflammatory conditions: primary ciliary dyskinesia (PCD), pneumonia and bronchial asthma. An “imaging ligand” allows for the subsequent visualization of the isolated cells using a sandwich technique. Five model strains of E. coli, MH-1, JM109, BL21, W3110 and ATCC25922, as well as B. subtilis and L. fermentum strains, each exhibiting distinct properties and expressing red fluorescent protein (RFP), were used as a phagocytosis substrate. Fluorometric, FTIR- and confocal laser scanning microscopy (CLSM) assessments of the phagocytic response of Mph to these bacterial cells were performed. Mph absorbed different strains of E. coli with different activities due to the difference in the surface villosity of bacterial cells (pili and fimbriae, as well as signal patterns). In the presence of other competitor cells (like those of Lactobacilli), the phagocytic activity of Mph is changed between two and five times and strongly dependent on the bacterial strain. The relative phagocytic activity indexes obtained for BALF-Mph in comparison with that obtained for model human CD206+ Mph in the M1 polarization state (derived from THP-1 monocyte cultures) were considered as a set of parameters to define the Mph polarization profile from the BALF of patients. Mannan as a marker determining the selectivity of the binding to the CD 206 mannose receptor of Mph significantly inhibited the phagocytosis of E. coli and B. subtilis in cases of pneumonia, suggesting an important role of CD206 overexpression in acute inflammation. Conversely, L. fermentum binding was enhanced in PCD, possibly reflecting altered macrophage responsiveness in chronic lung diseases. Our approach based on the profiling of Mph from patient BALF samples in terms of phagocytosis for a range of model bacterial strains is important for the subsequent detailed study of the factors determining dangerous conditions and resistance to existing therapeutic options.

24 June 2024 in CHILDREN INFECTIONS
Verified
Journal Article
Open access
PDF file
NKNataliya Kolganova
Nataliya Kolganova
DODmitry Ovsyannikov
Dmitry Ovsyannikov
AAA. E. Angel
A. E. Angel
MBM. V. Biryukova
M. V. Biryukova
SGSh. A. Gitinov
Sh. A. Gitinov
ДОД. Ю. Овсянников
Д. Ю. Овсянников
Mycoplasma pneumoniae (M. pn.), which is a well-known pathogen to cause atypical pneumonia, in 25% of cases can lead to a wide range of extra-pulmonary symptoms, reflecting damage to almost any organ or organ system (skin and mucous membranes, nervous, cardiovascular, gastrointestinal, urinary system etc.). Aspecific syndrome Mycoplasma pneumoniae-induced rash and mucositis (MIRM) has been identified recently. Among the CNS manifestations associated with M. pn., acute postinfectious cerebellar ataxia is worth mentioning. In this article we present clinical cases of a 14-year-old boy and a 6-year-old girl with extrapulmonary manifestations of M. pn. infection. This article considers etiological, pathogenetic and clinical features of mycoplasma infection in children with an emphasis on extra-respiratory manifestations.

13 December 2021 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
YNYu.Yu. Novikova
Yu.Yu. Novikova
DODmitry Ovsyannikov
Dmitry Ovsyannikov
AGA.A. Glazyrina
A.A. Glazyrina
NZN.N. Zvereva
N.N. Zvereva
SPS.S. Peters
S.S. Peters
YHYekaterinburg Sverdlovsk Oblast Regional Children’s Clinical Hospital
Yekaterinburg Sverdlovsk Oblast Regional Children’s Clinical Hospital
Coronavirus disease 2019 (COVID-19) in children in most cases is asymptomatic or mild, and its most severe late complication is multisystem inflammatory syndrome in children (MIS-C). The aim of the study is to find clinical, laboratory and instrumental characteristics, description of therapeutic tactics, including determination of the profile of patients requiring Tocilizumab prescription and the outcomes of MIS-C associated with COVID-19. Materials and methods of research: 245 children aged 3 months – 17 years old were included in the pilot prospective multicenter open-label comparative study with MIS-C associated with COVID-19, verified based on CDC criteria (2020). Results: the median age of patients was 8 [5; 10] years, boys predominated among the patients (57.1%); MIS-C manifested itself as a combination of the symptom complex of Kawasaki disease (KD, 53.1% of patients), more often of atypical form, cardiovascular (66.1%), gastrointestinal (61.2%), neurological (27.3%) symptoms and signs of detection of the urinary (29.4%) and respiratory (19.6%) systems; macrophage activation syndrome (MAS) was diagnosed in 19.5% of patients. Therapy included glucocorticosteroids (97.6%), antibiotics (95.5%), anticoagulants (93.9%), intravenous immunoglobulin (34.7%), vasoactive/vasopressor support (31.8%), Tocilizumab (15.1%), mechanical ventilation (2.4%), extracorporeal membrane oxygenation (0.4%). Patients receiving Tocilizumab, statistically significantly more often compared with patients without this therapy, were in the intensive care unit (ICU, 86.5% versus 40.9%, p<0.001), more often required vasopressor therapy (70.3% versus 25%, p<0.001), had statistically significantly higher markers of laboratory inflammatory activity. Treatment in 47.8% of cases was carried out in an ICU; one child has died. In 4.1%, according to echocardiography, coronaritis, ectasia of the coronary arteries without the formation of persistent aneurysms were detected. Conclusion: MIS-C associated with COVID-19 has clinical signs of KD, often of the incomplete form, accompanied by arterial hypotension/shock, MAS, which requires intensive therapy, and the prescription of Tocilizumab.

14 December 2020 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
YNYu.Yu. Novikova
Yu.Yu. Novikova
MHMoscow Morozov Children’s City Clinical Hospital
Moscow Morozov Children’s City Clinical Hospital
DODmitry Ovsyannikov
Dmitry Ovsyannikov
AGA.A. Glazyrina
A.A. Glazyrina
OZO.I. Zhdanova
O.I. Zhdanova
VGV.V. Gorev
V.V. Gorev
The most severe manifestation of the new coronavirus infection COVID-19 in children is the multisystem inflammatory syndrome in children (MIS-C). A systematic review of foreign publications as of July 25, 2020 contains an analysis of the disease course in 662 children with this syndrome and is used for comparison with the data obtained. Objective of the research: to characterize clinical manifestation, results of laboratory and instrumental studies, therapy, outcomes and consequences of the COVID-19- associated MIS-C, based on the observation of patients hospitalized to Morozov Children's City Clinical Hospital and Children’s clinical hospital of infectious diseases № 6 from May 1 to September 15, 2020. Materials and methods: the pilot study included 32 children aged 9 months – 15 years with COVID-19-associated MIS-C, verified based on WHO criteria (2020), including symptoms of Kawasaki disease (KD), arterial hypotension/shock, laboratory and instrumental signs of heart damage, signs of coagulopathy, gastrointestinal symptoms, increased inflammation markers, COVID-19 markers. Results: the median age of patients was 6 years, boys predominated among the patients (66%), all patients had antibodies to SARS-CoV-2 (31 children of the IgG class); MIS-C manifested itself as a combination of KD symptom complex (75% of patients) with arterial hypotension/shock (28%), neurological (50%), respiratory (41%), gastrointestinal (59%) symptoms; macrophage activation syndrome (MAS) was verified in 16% of patients. Therapy included intravenous immunoglobulin (75%), systemic glucocorticosteroids (88%), anticoagulants (91%), vasoactive/vasopressor support (31%). In 38% of cases treatment was performed in intensive care unit; one child died. According to echocardiography, 16% of patients had coronariitis, ectasia, and coronary arteries aneurysms. Conclusion: COVID-19-associated MIS-C is characterized by a severe course, cross-features with KD, shock syndrome with KD, MAS which requires intensive therapy and can cause acquired pathology of the cardiovascular system in children.

13 October 2023 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
NKNataliya Kolganova
Nataliya Kolganova
DODmitry Ovsyannikov
Dmitry Ovsyannikov
MAM.I. Ayrapetyan
M.I. Ayrapetyan
SBS.A. Bulynko
S.A. Bulynko
SGSh.A. Gitinov
Sh.A. Gitinov
RMRussian Federal Private Clinics Network Ao Gk Medsi
Russian Federal Private Clinics Network Ao Gk Medsi